UNSPSC 51392410: Dobutamine tartrate

This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D1IB9AI6J, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (- )-, (s-(r*,r*))-2,3-dihydroxybutanedioate (1:1) (salt) but more generally known as dobutamine tartrate, which bears US NIH Compound Identifier 208850. Most nations, for tariff and trade purposes, schedule dobutamine tartrate under HS 29222900 and SITC 51462.

As of Q4 2014, DOBUTAMINE TARTRATE remains US FDA's Preferred Term for this commodity. Dobutamine tartrate bears US NLM identifiers UMLS ID C0887392 and NCI Concept Code C65452. SMILES: CC(CCC1CCC(CC1)O)NCCC2CCC(C(C2)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51392410 Dobutamine tartrate is a Commodity code nominally for a single pharmaceutical product, but recent state and local opportunities tagged under it show minimal activity directly aligned with the code's scope. The single relevant recent solicitation — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2026 — seeks naloxone and drug deactivation systems for community health initiatives, not dobutamine specifically. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, addresses direct-to-manufacturer prescription programs at a system level and does not target dobutamine procurement. State and local jurisdictions appear to source pharmaceutical commodities through broader cooperative purchasing arrangements, group purchasing organizations, and pharmacy benefit managers rather than through narrowly tailored single-product solicitations.

The code shows limited recent discrete purchasing activity. Seminole County's opportunity represents a county health department acquisition executed through competitive bidding with quarterly deliveries to a specific health facility and a two-year initial contract term with one-year renewal options. Geographic spread is unclear from the available recent opportunities, as only Florida and Texas appear in the current records, and neither directly solicits dobutamine. Vendors pursuing pharmaceutical commodity codes at the state and local level should expect to compete primarily through existing cooperative purchasing vehicles, health plan formulary relationships, and group contracting arrangements rather than through direct RFPs or IFBs tied to specific drug products. The code's recent activity does not support pursuit as a primary focus area at this time.